Prostate Cancer

ARX517 showed early efficacy in patients with metastatic castration-resistant prostate cancer in the phase 1/2 APEX-01 study.

Insight into the expanding landscape of hormone therapies, including androgen receptor inhibitors and biosynthesis inhibitors, and their diverse applications in prostate cancer treatment.

Key opinion leader Benjamin Garmezy, MD, discusses the shifting landscape of prostate cancer management, the importance of identifying lethal cases, and the challenges in risk stratification and prognosis.

Adding niraparib to abiraterone acetate and prednisone was associated with an overall survival benefit compared with AAP alone in patients with BRCA1/2-mutated metastatic castration-resistant prostate cancer.

The addition of pembrolizumab to enzalutamide did not improve survival compared with enzalutamide alone in patients with metastatic castration-resistant prostate cancer.

Adding 177Lu-PSMA-617 to enzalutamide improved prostate-specific antigen progression-free survival in patients with metastatic castration-resistant prostate cancer.

Expert perspectives on the importance of forging collaborative relationships between urologists and medical oncologists in prostate cancer care, focusing on shared decision-making and patient-centric approaches.

Join David Morris, MD, FACS, and Benjamin Garmezy, MD, as they discuss their collaborative approach to treating advanced prostate cancer and the benefits it brings to patient care.

In an interview with Targeted Oncology, Rohan Garje, MD, discussed current treatment options for patients with prostate cancer and the role of PARP inhibitors.

During a Targeted Oncology™ Case-Based Roundtable™ event, Benjamin Garmezy, MD, discussed trial data that guides when to use cabazitaxel for patients with metastatic castration-resistant prostate cancer.

In a phase 2 trial, BXCL701 and pembrolizumab showed a significant increase in median overall survival time for patients with small cell neuroendocrine prostate cancer.

Data from the PROpel study support the FDA’s approval of olaparib plus abiraterone for patients with metastatic castration-resistant prostate cancer.

The disruption of the fine-tuned androgen receptor protein multivalent interactions might contribute to AR-related human pathologies.

Investigators presented results from new studies at the 2023 ASTRO Meeting. The data showcase a new assay’s performance in predicting metastasis-free survival and distant metastasis.

Additional findings from the phase 3 LIGHTHOUSE trial support flotufolastat F 18 injection and its approval in the prostate cancer space.

The phase 1/2 trial is evaluating 64Cu/67Cu SAR-Bombesin for diagnosis and treatment of castrate resistant prostate cancer.

In an interview with Targeted Oncology, Tanya B. Dorff, MD, discussed the role of goserelin and LHRH antagonists in the ever-changing treatment landscape for patients with prostate cancer.

Daniel P. Petrylak, MD, discusses background and findings from the phase 3 KEYNOTE-921 study of pembrolizumab plus docetaxel vs placebo plus docetaxel in patients with metastatic castration-resistant prostate cancer who had received prior next-generation hormonal agent therapy.

Robert Dreicer, MD, MS, MACP, FASCO, acknowledges that there have been substantial developments in therapies and strategies for treating prostate cancer, leading to heightened expectations of breakthroughs in the field.

During a Targeted Oncology™ Community Case Forum event in partnership with The Arizona Clinical Oncology Society, Alan H. Bryce, MD, reviewed data from clinical trials utilizing PARP inhibitors in patients with prostate cancer.

Findings from the largest group of patients with BRCA1/2-altered metastatic castration resistant prostate cancer are now available.

For prostate cancer awareness month, Bamidele A. Adesunloye, MD, MS, and Evan Pisick, MD, discussed recent changes and new developments that have been added to the treatment landscape.

During a Targeted Oncology™ Case-Based Roundtable™ event, Joshi Alumkal, MD, discussed selection of next-line therapy for a patient with metastatic castration-resistant prostate cancer who stopped docetaxel after 4 cycles.

A review of real-world data from the DEAR study of darolutamide, enzalutamide and apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer is given by Alicia Morgans, MD, MPH.